Výsledky vyhledávání - "Ayu WATANABE"

Akademický článek

Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis

Autor: Makoto Ito, Masahiro Kamata, Takeko Ishikawa, Hideaki Uchida, Shoya Suzuki, Ryosuke Takeshima, Ayu Watanabe, Itsumi Mizukawa, Shota Egawa, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Yayoi Tada

Publikováno v: Journal of Cutaneous Immunology and Allergy, Vol 6, Iss 5, Pp 152-158 (2023)

Abstract Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan in April 2018, and self‐injection of dupilumab has been available since May 2019. Subcutaneous self‐injection of medica

Externí odkaz: https://doaj.org/article/bf8f9473143e4fcba7849cbbc62924ca

Zobrazit plný text záznamu

Akademický článek

Analytical evaluation of fatty acid esters of hydroxy fatty acid quantity in fermented brown rice and rice bran (FRBA)

Autor: Ayu Watanabe, Laurence Balas, Daisuke Saigusa, Jiro Ogura, Thierry Durand, Nariyasu Mano, Hiroaki Yamaguchi

Publikováno v: Food Chemistry Advances, Vol 1, Iss , Pp 100040- (2022)

Fermented brown rice and rice bran with Aspergillus oryzae (FBRA) is a processed food known to have anti-inflammatory and anti-tumorigenic effects. Moreover, suppressive effects on spontaneous type-1 diabetes have recently been reported in mice. The

Externí odkaz: https://doaj.org/article/3cc164073ec4496c923a2a49b7ebef8d

Zobrazit plný text záznamu

Akademický článek

Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient’s symptoms

Autor: Takahiro Osawa, Takashige Abe, Hiroshi Kikuchi, Ryuji Matsumoto, Sachiyo Murai, Takafumi Nakao, Shinji Tanaka, Ayu Watanabe, Nobuo Shinohara

Publikováno v: PLoS ONE, Vol 17, Iss 3 (2022)

Background Immune checkpoint inhibitors (ICIs) are increasingly being used to treat malignancies. Some patients experience immune-related adverse events (irAEs), which may affect any organ/tissue. IrAEs are occasionally fatal and usually have nonspec

Externí odkaz: https://doaj.org/article/6df839f38b29467fb61e0e68f328ad3a

Zobrazit plný text záznamu

Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms

Autor: Takahiro Osawa, Takashige Abe, Hiroshi Kikuchi, Ryuji Matsumoto, Sachiyo Murai, Takafumi Nakao, Shinji Tanaka, Ayu Watanabe, Nobuo Shinohara

Publikováno v: PloS one. 17(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f5d609d77c4a151420f3c64f5110da
https://pubmed.ncbi.nlm.nih.gov/35290407

Zobrazit plný text záznamu

Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis

Autor: Itsumi Mizukawa, Shota Egawa, Ryosuke Takeshima, Teruo Shimizu, Ayu Watanabe, Hideaki Uchida, Masahiro Kamata, Makoto Ito, Yayoi Tada

Publikováno v: Journal of dermatological science. 104(1)

Background Apremilast, a selective inhibitor of the enzyme phosphodiesterase 4, is efficacious for psoriasis. However, detailed in vivo effects of apremilast on psoriasis remain to be elucidated. Objective To examine the in vivo effects of apremilast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::496983ba61eb7dc66d36d85978519669
https://pubmed.ncbi.nlm.nih.gov/34548208

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání